Journal ArticleDOI
p53 mutations in cancer
Reads0
Chats0
TLDR
Some of the emerging molecular mechanisms through which mutant p53 proteins can exert oncogenic functions, including invasion, metastasis, proliferation and cell survival, are highlighted.Abstract:
In the past fifteen years, it has become apparent that tumour-associated p53 mutations can provoke activities that are different to those resulting from simply loss of wild-type tumour-suppressing p53 function. Many of these mutant p53 proteins acquire oncogenic properties that enable them to promote invasion, metastasis, proliferation and cell survival. Here we highlight some of the emerging molecular mechanisms through which mutant p53 proteins can exert these oncogenic functions.read more
Citations
More filters
Journal ArticleDOI
The Human Transcription Factors.
Samuel A. Lambert,Arttu Jolma,Laura F. Campitelli,Pratyush Kumar Das,Yimeng Yin,Mihai Albu,Xiaoting Chen,Jussi Taipale,Jussi Taipale,Jussi Taipale,Timothy P. Hughes,Matthew T. Weirauch,Matthew T. Weirauch +12 more
TL;DR: This review considers how TFs are identified and functionally characterized, principally through the lens of a catalog of over 1,600 likely human TFs and binding motifs for two-thirds of them, highlighting the importance of continued effort to understand TF-mediated gene regulation.
Journal ArticleDOI
The Next Generation of Platinum Drugs: Targeted Pt(II) Agents, Nanoparticle Delivery, and Pt(IV) Prodrugs
TL;DR: Recently, there has been a surge of activity, based on a great deal of mechanistic information, aimed at developing nonclassical platinum complexes that operate via mechanisms of action distinct from those of the approved drugs as mentioned in this paper.
Journal ArticleDOI
Combination therapy in combating cancer.
Reza Bayat Mokhtari,Reza Bayat Mokhtari,Tina S. Homayouni,Narges Baluch,Evgeniya Morgatskaya,Sushil Kumar,Bikul Das,Herman Yeger +7 more
TL;DR: An approach that combines repurposed pharmaceutical agents with other therapeutics has shown promising results in mitigating tumour burden, and this systematic review discusses important pathways commonly targeted in cancer therapy.
Journal ArticleDOI
Mutant p53 in Cancer: New Functions and Therapeutic Opportunities
TL;DR: There is growing evidence that these mutant p53s have both lost wild-type p53 tumor suppressor activity and gained functions that help to contribute to malignant progression.
Journal ArticleDOI
Unravelling mechanisms of p53-mediated tumour suppression
TL;DR: The roles of classical p53 functions, as well as emerging p53-regulated processes, in tumour suppression are discussed.
References
More filters
Journal ArticleDOI
Mdm2 promotes the rapid degradation of p53
TL;DR: It is proposed that the Mdm2-promoted degradation of p53 provides a new mechanism to ensure effective termination of the p53 signal.
Journal ArticleDOI
Regulation of p53 stability by Mdm2
TL;DR: It is shown that interaction with Mdm2 can also result in a large reduction in p53 protein levels through enhanced proteasome-dependent degradation, which may contribute to the maintenance of low p53 concentrations in normal cells.
Journal ArticleDOI
Blinded by the Light: The Growing Complexity of p53
Karen H. Vousden,Carol Prives +1 more
TL;DR: Control of p53's transcriptional activity is crucial for determining which p53 response is activated, a decision that must be understood if the next generation of drugs that selectively activate or inhibit p53 are to be exploited efficiently.
Journal ArticleDOI
Crystal structure of a p53 tumor suppressor-DNA complex: Understanding tumorigenic mutations
TL;DR: The crystal structure of a complex containing the core domain of human p53 and a DNA binding site provides a framework for understanding how mutations inactivate it, and supports the hypothesis that DNA binding is critical for the biological activity of p53.
Journal ArticleDOI
Senescence and tumour clearance is triggered by p53 restoration in murine liver carcinomas
Wen Xue,Lars Zender,Cornelius Miething,Ross A. Dickins,Ross A. Dickins,Eva Hernando,Valery Krizhanovsky,Carlos Cordon-Cardo,Scott W. Lowe,Scott W. Lowe +9 more
TL;DR: It is indicated that p53 loss can be required for the maintenance of aggressive carcinomas, and illustrates how the cellular senescence program can act together with the innate immune system to potently limit tumour growth.